See All Slides - tctmd.com

Slides

Presentation TCT 2017

Insights From New Meta-Analyses of PCI vs CABG for Left Main Revascularization

Presenter: Antonio Colombo, David E. Kandzari, Davide Capodanno

October 31, 2017

Presentation TCT 2017

EVOLUT R TAVR Technology Review (Including EVOLUT 34mm and PRO) and Clinical Program Updates

Presenter: John K. Forrest

October 31, 2017

Presentation TCT 2017

Debate: Should CHIP Success Be Defined by Complete Revascularization? Con!

Presenter: Farouc Jaffer, Ajay J. Kirtane

October 31, 2017

Presentation TCT 2017

Intracoronary Pharmacology: Approach to Thrombus and the Prevention and Treatment of No Reflow

Presenter: David P. Faxon, Robert S. Schwartz, Raffaele Piccolo

October 31, 2017

Presentation TCT 2017

ABSORB II at 4 Years: Clinical Outcomes Beyond the Cusp of Complete Bioresorption

Presenter: Azeem Latib, Bernard R. Chevalier

October 31, 2017

Presentation TCT 2017

Synthesis of Randomized Trial and Registry Data for Devices in Cardiogenic Shock: What Is the Evidence for Efficacy?

Presenter: Vladimir Dzavik, Navin K. Kapur, Nicolas M. Van Mieghem

October 31, 2017

Presentation TCT 2017

CMS Strategy and the Move to Value

Presenter: Peter L Duffy, Hadley Wilson, John A. Spertus

October 31, 2017

Presentation TCT 2017

Embolic Protection Devices For TAVR Procedures: Lessons Learned From SENTINEL and Other Experiences

Presenter: Martin B. Leon, Changfu Wu

October 31, 2017

Presentation TCT 2017

Established TMVR 1: Cardiaq - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, James B. Hermiller Jr.

October 31, 2017

Presentation TCT 2017

Outcomes and Clinical Implications From the Euro-CTO Trial

Presenter: Barry D. Rutherford, Robert W. Yeh, Gerald S. Werner

October 31, 2017

Advertisement

Slides

Insights From New Meta-Analyses of PCI vs CABG for Left Main Revascularization

EVOLUT R TAVR Technology Review (Including EVOLUT 34mm and PRO) and Clinical Program Updates

Debate: Should CHIP Success Be Defined by Complete Revascularization? Con!

Intracoronary Pharmacology: Approach to Thrombus and the Prevention and Treatment of No Reflow

ABSORB II at 4 Years: Clinical Outcomes Beyond the Cusp of Complete Bioresorption

Synthesis of Randomized Trial and Registry Data for Devices in Cardiogenic Shock: What Is the Evidence for Efficacy?

CMS Strategy and the Move to Value

Embolic Protection Devices For TAVR Procedures: Lessons Learned From SENTINEL and Other Experiences

Established TMVR 1: Cardiaq - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Outcomes and Clinical Implications From the Euro-CTO Trial

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content